Evicenter
P&T meetings

Ulixacaltamide

Essential tremor

Regulatory submission
NDA submitted by February 2026
Launch
Not announced
Last updated
78 sources

Company-reported prevalence

Ulixacaltamide

Overview

FieldValue
DrugUlixacaltamide
IndicationEssential tremor
DiseaseEssential tremor (ET)
CompanyPraxis Precision Medicines; no licensee or co-development partner holding rights to ulixacaltamide is named in the report or in the documents searched (Remagine Labs collaborates with Praxis on a transdermal formulation, announced July 2026)
Documents searchedCorporate website pages (home, pipeline, clinical trials), October 2026; Essential to Me disease awareness website, patient pages and healthcare professional pages, October 2026; press releases naming ulixacaltamide or essential tremor, October 2023 to October 2026; press release, August 8, 2023; Form 10-K for 2025, February 19, 2026; Form 10-Q for the quarter ended March 31, 2026, May 2026; Form 10-Q for the quarter ended June 30, 2026, August 6, 2026; corporate presentation, August 2026; Essential3 topline results presentation, October 16, 2025; presentation at the American Academy of Neurology Annual Meeting, April 2024; scientific posters at the American Academy of Neurology Annual Meeting, April 2026
Data as ofOctober 14, 2026
Prepared byAI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Number affected: Praxis Precision Medicines press release, August 2026

“ET is one of the most common movement disorders, affecting approximately seven million patients in the U.S.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Praxis Precision Medicines (2026) press release, August 6, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: Praxis Precision Medicines Form 10-K for 2025, February 2026

“ET is one of the most common movement disorders, affecting roughly seven million people in the United States alone, representing a multi-billion dollar commercial opportunity.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Praxis Precision Medicines (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Eligible population: Praxis Precision Medicines Form 10-K for 2025, February 2026

“in the United States alone” (opens the source at this quote in a new tab)

“The vast majority of patients are left without a treatment option, with an estimated minimum of two million patients currently seeking treatment.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Praxis Precision Medicines (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Eligible population: Praxis Precision Medicines press release, December 2025

“in the United States alone” (opens the source at this quote in a new tab)

“The vast majority of patients are left without a treatment option, with estimated minimum of 2 million patients seeking treatment.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Praxis Precision Medicines (2025) press release, December 29, 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number diagnosed: Praxis Precision Medicines press release, August 2023

“Essential Tremor (ET) is the most common movement disorder, affecting roughly seven million people in the United States alone, including approximately two million diagnosed patients.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Praxis Precision Medicines (2023) press release, August 8, 2023, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: Praxis Precision Medicines corporate presentation, August 2026

“An estimated 7 million people in the U.S. live with ET” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Praxis Precision Medicines (2026) corporate presentation, August 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 8 of 30 (opens in a new tab)

Number affected: Praxis Precision Medicines presentation at the American Academy of Neurology Annual Meeting, April 2024

“Up to 7 million people in the United States may have ET” (opens the source at this quote in a new tab)

Cited source: 2.3 Ghosh 2016

Praxis Precision Medicines (2024) presentation at the American Academy of Neurology Annual Meeting, April 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 3 of 15 (opens in a new tab)

Number affected: Praxis Precision Medicines Essential to Me website for healthcare professionals, October 2026

“7M” (opens the source at this quote in a new tab)

“Americans estimated to have Essential Tremor” (opens the source at this quote in a new tab)

Cited source: 2.1 Vetterick 2022

Praxis Precision Medicines (2026) Essential to Me website for healthcare professionals, Understanding ET page, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: Praxis Precision Medicines Essential to Me patient website, October 2026

“Did you know that Essential Tremor affects about 7 million Americans?” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Praxis Precision Medicines (2026) Essential to Me patient website, What You Need to Know page, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Europe

No evidence found.

Global

No evidence found.

Other countries and regions

No evidence found.

Geography not stated

Prevalence (people over 65 years old): Praxis Precision Medicines Essential to Me patient website, October 2026

“The risk increases with age, affecting about 6% of the population over 65 years old.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Praxis Precision Medicines (2026) Essential to Me patient website, What You Need to Know page, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Prevalence: Praxis Precision Medicines Essential to Me website for healthcare professionals, October 2026

“Age is a risk factor for Essential Tremor, with the prevalence estimated to increase by 74% for every decade of life.” (opens the source at this quote in a new tab)

“In some studies, prevalence exceeds 20% for patients in their 80s and 90s” (opens the source at this quote in a new tab)

Cited source: 2.2 Louis 2021

Praxis Precision Medicines (2026) Essential to Me website for healthcare professionals, Understanding ET page, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number treated: Praxis Precision Medicines presentation at the American Academy of Neurology Annual Meeting, April 2024

“1 million patients with ET remain untreated” (opens the source at this quote in a new tab)

“~1 million people are diagnosed with ET and on treatment, while another 1 million are estimated to remain untreated” (opens the source at this quote in a new tab)

Cited source: 2.4 Praxis Precision Medicines, undated; 2.1 Vetterick 2022

Praxis Precision Medicines (2024) presentation at the American Academy of Neurology Annual Meeting, April 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 4 of 15 (opens in a new tab)

Sources the company cites

Vetterick 2022

Reference as the company lists it, Essential to Me website for healthcare professionals, Understanding ET page

“Vetterick C, Lyons KE, Matthews LG. The hidden burden of disease and treatment experiences of patients with essential tremor: a retrospective claims data analysis. Adv Ther. 2022;39(12):5546-5567.” (opens the source at this quote in a new tab)

Praxis Precision Medicines (2026) Essential to Me website for healthcare professionals, Understanding ET page, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Reference as the company lists it, presentation at the American Academy of Neurology Annual Meeting, April 2024

“Vetterick C, et al. Adv Ther. 2022;39(12):5546-5567” (opens the source at this quote in a new tab)

Praxis Precision Medicines (2024) presentation at the American Academy of Neurology Annual Meeting, April 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 4 of 15 (opens in a new tab)

Passage carrying the figure

“In the USA, it is projected that approximately 7 million people have ET, representing more than 2% of the total population” (opens the source at this quote in a new tab)

“Our findings from a large US insurance database revealed that approximately 1 million people were diagnosed and actively sought pharmacologic treatment for ET from 2015 through 2019; however, projected US population estimates of approximately 2 million diagnosed and current treatment rates suggest that a further 1 million patients remain untreated.” (opens the source at this quote in a new tab)

Vetterick 2022, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Louis 2021

Reference as the company lists it

“Louis ED, McCreary M. How common is essential tremor? Update on the worldwide prevalence of essential tremor. Tremor Other Hyperkinet Mov (NY). 2021;11:28.” (opens the source at this quote in a new tab)

Praxis Precision Medicines (2026) Essential to Me website for healthcare professionals, Understanding ET page, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the figure

“We estimated that the prevalence increases by a factor of 1.74, or 74%, for every decade increase in age” (opens the source at this quote in a new tab)

“Values in excess of 20% are observed during the ninth and tenth decade of life” (opens the source at this quote in a new tab)

Louis 2021, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Ghosh 2016

Reference as the company lists it

“1. GHOSH (2016) (P.231, C.1, PH.1, L.1-2)” (opens the source at this quote in a new tab)

Praxis Precision Medicines (2024) presentation at the American Academy of Neurology Annual Meeting, April 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 3 of 15 (opens in a new tab)

Passage carrying the figure

Not quoted: The reference gives an author surname, a year, and a page location only, with no title, journal, or publisher, and no document matching it could be identified.

Praxis precision medicines, undated

Reference as the company lists it

“Source: Praxis Data on File; Vetterick C, et al. Adv Ther. 2022;39(12):5546-5567” (opens the source at this quote in a new tab)

Praxis Precision Medicines (2024) presentation at the American Academy of Neurology Annual Meeting, April 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 4 of 15 (opens in a new tab)

Passage carrying the figure

Not quoted: Unpublished company data; no document is available to read.

References

  1. Louis 2021 (opens in a new tab)
  2. Praxis Precision Medicines (2023) press release, August 8, 2023 (opens in a new tab)
  3. Praxis Precision Medicines (2024) presentation at the American Academy of Neurology Annual Meeting, April 2024 (opens in a new tab)
  4. Praxis Precision Medicines (2025) press release, December 29, 2025 (opens in a new tab)
  5. Praxis Precision Medicines (2026) corporate presentation, August 2026 (opens in a new tab)
  6. Praxis Precision Medicines (2026) Essential to Me patient website, What You Need to Know page (opens in a new tab)
  7. Praxis Precision Medicines (2026) Essential to Me website for healthcare professionals, Understanding ET page (opens in a new tab)
  8. Praxis Precision Medicines (2026) Form 10-K for 2025 (opens in a new tab)
  9. Praxis Precision Medicines (2026) press release, August 6, 2026 (opens in a new tab)
  10. Vetterick 2022 (opens in a new tab)